ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 is administered via subcutaneous injection at 2-4 mg daily once daily. Subcutaneous injections into the abdominal fat or thigh are most common. Proper reconstitution with bacteriostatic water is required first.
How Do You Inject ARA-290?
ARA-290 is administered via subcutaneous injection. For most researchers, subcutaneous injection is the standard approach — it's simple, relatively painless, and effective for Innate repair receptor agonist, anti-inflammatory peptide compounds.
This guide covers injection technique, site selection, needle choices, and common mistakes.
How Do You Prepare for a ARA-290 Injection?
Step 1: Wash your hands thoroughly.
Step 2: Clean the top of the ARA-290 vial and BAC water vial with alcohol swabs. If not yet reconstituted, see our ARA-290 reconstitution guide.
Step 3: Draw your dose (2-4 mg daily) into an insulin syringe. Use our calculator for exact units.
Step 4: Clean the injection site with an alcohol swab and let it dry.
What Is the Correct Injection Technique?
Subcutaneous (most common): Pinch a fold of skin — typically abdominal fat 2+ inches from the navel, or the thigh. Insert the needle at a 45-degree angle. Push the plunger slowly and steadily. Hold for 5 seconds, then withdraw.
Intramuscular (less common for ARA-290): Insert the needle at 90 degrees into the muscle (deltoid or vastus lateralis). This route provides faster absorption but isn't necessary for most peptide protocols.
Rotate injection sites to prevent lipodystrophy (fat tissue changes from repeated injections in the same spot).
What Size Needle Should You Use?
For subcutaneous ARA-290 injections, 29-31 gauge insulin needles (½ inch or 8mm) are standard. These are thin enough to be nearly painless while long enough for proper subcutaneous delivery.
Use a fresh needle for every injection. Never reuse or share needles.
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →What Are Common Injection Side Effects?
Mild redness, swelling, or itching at the injection site is normal and typically resolves within hours. Small bruises can occur, especially if you hit a capillary.
If you experience persistent pain, swelling, warmth, or redness lasting more than 24 hours, discontinue and consult a healthcare provider — these may indicate infection.
Bottom Line on ARA-290 Injection
ARA-290 is administered via subcutaneous injection at 2-4 mg daily once daily. Subcutaneous injection with a 29-31 gauge insulin needle into abdominal fat is the standard technique. Rotate sites and use a fresh needle every time.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.